<DOC>
	<DOCNO>NCT00440128</DOCNO>
	<brief_summary>The purpose study evaluate effect study drug ( GW679769 ) commonly use chemotherapy drug ( docetaxel ) give I.V . Blood sample take see GW679769 alters blood level chemotherapy . The study last 2 week final follow-up visit 6 week later .</brief_summary>
	<brief_title>The Effects Of GW679769 ( Casopitant ) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<mesh_term>Neurokinin-1 Receptor Antagonists</mesh_term>
	<criteria>Male female 18 year age A female eligible enter participate study : 1 . Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include female least one following : Has hysterectomy , Has bilateral oophorectomy ( ovariectomy ) , Has bilateral tubal ligation , • Is consider postmenopausal ( define amenorrheic ≥ 1 year ) serum follicle stimulate hormone ( FSH ) serum estradiol concentration consistent postmenopausal status . 2 . Childbearing potential , negative serum pregnancy negative urine pregnancy test within 24 hour prior administration first dose study medication agree one following : Complete abstinence sexual intercourse two week prior administration first dose investigational product 30 day final dose study medication . Use doublebarrier contraception ( condom spermicidal jelly , foam suppository , film ; diaphragm spermicide ; male condom diaphragm ) two week prior administration first dose investigational product 30 day final dose study medication . Vasectomized partner document sterile prior female subject 's entry sole sexual partner female . NOTE : woman childbearing potential enrol , must use doublebarrier contraception addition oral contraceptive active study treatment period 6 week final dose study medication . Histologically confirm malignant solid tumor schedule receive least 2 course chemotherapy docetaxel single intravenous dose 20 40 mg/m2 give duration one hour repeat weekly . Received eight few previous dos docetaxel . Subjects receive eight dos docetaxel must receive permission GSK medical monitor order eligible study . ECOG performance status score less equal 2 NOTE : If subject 's performance status deteriorate screen Visit time first dose study drug score &gt; 2 , subject exclude study Adequate hematologic physiological organ function evidence Absolute Neutrophil Count ≥1500/mm3 . Platelets ≥ 100,000/mm3 Hemoglobin ≥ 9 g/dL Serum creatinine &lt; 1.5 mg/dL Total Bilirubin ≤ upper limit reference range Aspartate Transaminase ( AST ) &lt; 2 x upper limit reference range Alanine Transaminase ( ALT ) &lt; 2 x upper limit reference range Alkaline Phosphatase &lt; 2.5 x upper limit reference range . Calculated creatinine clearance &gt; 50 mL/min ( measure Cockcroft Gault Formula ; ) Written informed consent obtain prior studyspecific procedure assessment . Able swallow retain oral medication . Pregnant lactating . Received radiation therapy abdomen pelvis 28 day prior receive first dose study medication schedule receive radiation therapy abdomen pelvis six day follow first dose study medication . Received dose docetaxel week prior Day 1 . Known central nervous system primary metastatic malignancy , unless successfully treat excision radiation stable least 3 month prior receive first dose study medication . Active systemic infection poorly control medical condition ( malignancy ) , opinion investigator , may confound result study pose unwarranted risk subject . Subjects previous , current , history alcoholism may permit provide , investigator 's opinion , subject 's disease state confound result study . Receiving regular treatment high dose systemic corticosteroid therapy steroid dose within 72 hour prior receive first dose study medication . Topical steroid inhale corticosteroid steroid dose less equal 10 mg prednisone daily ( equivalent ) permit subject dose least 14 day prior dose . Hypersensitivity contraindication ondansetron 5HT3 receptor antagonist , dexamethasone , docetaxel , casopitant , component mention medication . Received investigational drug within 28 day five halflives ( whichever longer ) prior receive first dose study medication , schedule receive investigational drug study . Use strong inhibitor CYP3A4 CYP3A5 prior first dose study medication Use inducer CYP3A4 CYP3A5 ( steroid describe Exclusion Criteria 5 ) within 14 day prior first dose study medication Use drug narrow therapeutic index interact Pglycoprotein pathway within 14 day prior first dose study medication 14 day last dose docetaxel include digoxin . Use drug narrow therapeutic index metabolize CYP2C8 within 14 day prior first dose study medication include repaglinide torsemide . Disease significantly affect absorption oral medication . Inadequate venous access pharmacokinetic sampling . Unresolved Grade 2 bad toxicity prior therapy . Active peptic ulcer disease ( PUD ) history PUD unknown etiology . NOTE : Subject eligible enter participate study history PUD know etiology documentation gastroenterologist qualify physician etiology PUD effective treatment provide full eradication ulcer symptom . Subjects present symptom gastroesophageal reflux disease ( GERD ) eligible . However , investigator suspect PUD subject , subject must GI assessment rule PUD . If assessment negative , subject may enter study . For subject , appropriate step must also take minimize risk reoccurrence . If PUD nonsteroidal antiinflammatory drug ( NSAID ) induce , subject longer take NSAID medication ( ) . If PUD induce H. pylorus , subject appropriately treat . Stool positive occult blood . Test may repeat subject abstain red meat previous three day . Pepsinogen level lower limit laboratory reference range ( LLRR ) . Troponin level 10 % coefficient variation assay determine laboratory perform test . Calculated QT interval ( QTc ) &gt; 480 msec . Clinically significant cardiac disease would interfere participation study determine investigator . Known suspected iron deficiency . Use NSAIDS , include aspirin dose , include COX2 inhibitor . These medication prohibit 7 day prior administration study drug duration study 72 hour last dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Casopitant ,</keyword>
	<keyword>Neurokinin-1 Receptor Antagonist ,</keyword>
	<keyword>Drug-Interaction ,</keyword>
	<keyword>CYP3A</keyword>
	<keyword>NK-1 Receptor Antagonist ,</keyword>
	<keyword>GW679769 ,</keyword>
	<keyword>Docetaxel ,</keyword>
</DOC>